<div><p><b>Background:<span> </b>IL-17 signaling is implicated in the pathogenesis of alcohol-associated liver disease (AALD) leading to steatosis, fibrosis and hepatocellular carcinoma (HCC). We recently demonstrated that the specific deletion of IL-17RA in hepatocytes protects from steatosis, fibrosis and HCC in high fat diet plus ethanol (HFD+EtOH)-fed in MUP uPA mice (model that express urokinase-type plasminogen activator driven by a hepatocyte promoter for major urinary protein).

<div><p><b>Background:</p> </b><p>Primary Sclerosing Cholangitis (PSC) manifests with fibrotic scarring of the intrahepatic and extrahepatic bile ducts due to an immune-mediated inflammatory response. The cyclic GMP–AMP synthase –stimulator of interferon genes (cGAS-STING) signaling pathway is a key mediator of inflammatory gene expression and cytokine release in response to cellular stress. The inflammatory milieu observed in PSC recruits immune cells, including neutrophils, to infiltrate the peri-portal region.

<div><p><strong><b>Background:</strong> </b>Several studies in adults showed that spleen stiffness measurement (SSM) by vibration-controlled transient elastography (VCTE) can accurately assess clinically significant portal hypertension (HTN) and predict presence of esophageal varices. However, pediatric studies on SSM published thus far have used a liver-specific probe to measure the spleen making them difficult to interpret and possibly overestimating SSM, as the spleen is inherently a stiffer organ than the liver.

<div><p><b>Background:<span> </b>Patients with cirrhosis have increased surgical risk compared to the general population. Preoperative optimization by nonsurgical clinicians improves postoperative outcomes after colectomy in studies of patients with major comorbidities, however, data specific to patients with cirrhosis and addressing more diverse surgeries are limited.

<div><p><b>Background: </b>About 30% of patients with PBC have a suboptimal response to ursodeoxycholic acid (UDCA), leading to a worse prognosis. In the phase III POISE trial, response to obeticholic acid (OCA) was assessed by using the POISE score. Recently, complete biochemical normalization (normal ALP and bilirubin ≤ 0.6 ULN) has been proposed as a new therapeutic aim in PBC, as it significantly improves liver-related and overall survival, but the effectiveness of second-line therapy for this new therapeutic target has not been evaluated.</p>

<div><p><b>Background: </b>We reported the HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg/HBcAg mixed with mucoadhesive excipient carboxy-vinyl polymer (CVP-NASVAC) in chronically HBV infected patients. This study was aimed to assess the long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses.</p>

<div><p><b>Background:</p> </b><p>Chronic inflammation due to various etiologies leads to liver fibrosis and subsequently cirrhosis. The liver lymphatic system helps to reduce inflammation. We hypothesized that the liver lymphatic system ameliorates liver fibrosis/cirrhosis.</p>

<div><p><b>Background: </b>Alagille syndrome (ALGS) is a rare, genetic, multisystem disorder in which cholestatic liver disease is common and that may include clinical manifestations of severe pruritus and elevated bile acids (BAs). The efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, were assessed in patients with ALGS in the phase 3 ASSERT and ASSERT-EXT trials. Using data from these studies, we analyzed the effects of odevixibat on pruritus and BAs over time.</p>

<div><p><b>Background: </b>FDA recommended histopathological end-points for NASH clinical trials may not be fully evaluated by conventional histological staging. Shorter time frames in NASH trials make it difficult to assess changes in treatment-induced fibrosis with current classification systems. Assessment of specific morphological fibrosis parameters and their quantification in specific zones of NASH-CRN classification, can be done by SHG/TPE-based AI platforms.

<div><p><b>Background:</p> </b><p style="font-weight: 400;">This study was performed to examine the effect of empagliflozin on liver fat content in T2DM patients and in nondiabetic individuals, and the relationship between the decrease in liver fat and other metabolic actions of empagliflozin.</p>